ViiV Healthcare announces positive week 48 results from TANGO study of dolutegravirlamivudine

ViiV Healthcare announces positive week 48 results from TANGO study of dolutegravir/lamivudine

07:07 EDT 25 Jul 2019 | Pharmaceutical Business Review

Full Week 48 findings were presented today at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City. Kimberly Smith, MD, Head of Global

More From BioPortfolio on "ViiV Healthcare announces positive week 48 results from TANGO study of dolutegravir/lamivudine"